ADI-PEG20 Phase 3 Trial Shows Promise: ATOMIC-Meso Results
ATOMIC-Meso Phase 3 trial shows ADI-PEG20 plus chemotherapy improves survival in pleural mesothelioma. Analysis of this arginine-depleting therapy.
Articles by James
TEAD Inhibitor IK-930 Shows Activity in Mesothelioma: ESMO Update
TEAD inhibitor IK-930 shows clinical activity in NF2-mutated mesothelioma at ESMO. First targeted therapy for this genetic subtype.
UV1 Cancer Vaccine Receives FDA Fast Track for Mesothelioma
FDA grants Fast Track to UV1 telomerase vaccine for mesothelioma. Combined with immunotherapy, UV1 showed 64% response rate in trials.
93 Clinical Trials Are Recruiting Mesothelioma Patients Right Now. Here's What's Being Tested.
93 mesothelioma trials recruiting now. Immunotherapy leads with 32 trials, CAR-T emerges with 5. Complete 2026 data by state, phase, and treatment type.
Hopkins Trial: Immunotherapy Before and After Surgery Aids Mesothelioma Patients
Johns Hopkins trial shows pre/post-surgery nivolumab + ipilimumab safe for operable mesothelioma, with 28.6-month median survival.
The Asbestos Cover-Up: What the Industry Knew in 1930
Company memos reveal asbestos manufacturers knew their products were killing workers decades before warning anyone. The paper trail of corporate deception.
3,000 Americans Die From Mesothelioma Yearly
Who is dying from mesothelioma in America: veterans, construction workers, and people who never worked with asbestos. The numbers behind the epidemic.
New Review Maps BAP1 Loss in Mesothelioma
New Oncogene review maps BAP1 loss mechanisms in mesothelioma. 65% of cases involve BAP1 inactivation; EZH2 inhibitors emerge as potential targeted therapy.
UK, EU Split on Talc Cancer Classification
UK declines to classify talc as a carcinogen while EU recommends Category 1B classification, creating regulatory uncertainty for cosmetics.
Cell Therapy Shrinks Tumors in 63%
A new cell therapy achieved tumor shrinkage in 63% of advanced mesothelioma patients—more than double typical response rates.
Mesothelioma Treatment Advances: 2025
2025 saw major mesothelioma treatment advances including TEAD inhibitors, bispecific antibodies, and perioperative immunotherapy. Here's the full review.
Drug Combo Achieves 60% Response Rate
A Dutch trial found two drugs achieved a 60% response rate in mesothelioma patients whose cancer returned after immunotherapy.
FDA Withdraws Talc Asbestos Testing Rule
FDA withdrew its rule requiring asbestos testing in cosmetic talc. Public health advocates warn of ongoing contamination risks.
One Drug Halted, Another Advances
Novartis halted one experimental mesothelioma drug, but a competitor's TEAD inhibitor shows strong results in clinical trials.
Mesothelioma Survival: 18-Year Survivor's Story
Diagnosed with peritoneal mesothelioma while pregnant, this survivor shares her 18-year journey and the reality of living with this rare cancer long-term.
Mesothelioma Awareness Day: September 26
September 26 is Mesothelioma Awareness Day. Learn about the history of awareness efforts, current statistics, and how to get involved.
Mesothelioma Treatment: Hopkins Immunotherapy Trial
Johns Hopkins phase 2 trial shows pre- and post-surgery immunotherapy is safe and effective for operable mesothelioma, with 28.6-month median survival.
VT3989 Doubles Time Without Progression
Patients on VT3989 went 40 weeks without cancer progression—vs. 15 weeks on standard chemo. FDA granted Fast Track status.
Immunotherapy Trial NCT06503146 (NCI): Phase 2 Study for Mesothelioma
National Cancer Institute (NCI) PHASE2 clinical trial testing immunotherapy for mesothelioma patients. Trial NCT06503146 is now recruiting.
Hopkins: Pre-Surgery Immunotherapy Success
A Johns Hopkins trial found that immunotherapy before and after surgery extended median survival to 28.6 months, 10 months longer than average.
Trial Tests Immunotherapy Before Surgery
Baylor and Duke are testing immunotherapy before surgery for mesothelioma. Trial now enrolling operable patients.
IMPALA Trial: Light Therapy for Mesothelioma
The IMPALA trial in France is testing intrapleural photodynamic therapy combined with nivolumab for inoperable mesothelioma. Results expected mid-2026.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT07121374)
University Hospital, Antwerp PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma patients. Trial NCT07121374 is now recruiting.
CAR-T Trial NCT06885697 (NCI): Phase 1 Study for Mesothelioma
National Cancer Institute (NCI) PHASE1 clinical trial testing CAR-T cell therapy for mesothelioma patients. Trial NCT06885697 is now recruiting.
Asbestos Disclosure Bill H.R.4247
H.R.4247 would require sellers and landlords to disclose known asbestos hazards before completing sales or leases of residential properties.
Dual-Target Immunotherapy Shows 52% Response
BioNTech's dual-target immunotherapy achieved a 52% response rate in mesothelioma patients. Results presented at ASCO 2025.
UK Commits £1.2B for Asbestos Removal
UK government allocates £470 million for 656 schools and £750 million for NHS sites to address asbestos, crumbling infrastructure in 2025-2026.
FDA Approves Opdivo Qvantig for Mesothelioma
FDA approval of Opdivo Qvantig allows subcutaneous nivolumab delivery in under 5 minutes, compared to 30-minute IV infusions for mesothelioma patients.
Nivolumab + Ipilimumab Phase 2 Trial for Mesothelioma
Alliance phase 2 trial testing nivolumab + ipilimumab for mesothelioma. NCT05647265 is now recruiting patients.
KEYNOTE-483: Keytruda Combo Approved
KEYNOTE-483 Phase 3 trial shows pembrolizumab plus chemotherapy improves survival to 17.3 months. FDA approved September 2024 for first-line treatment.
Pembrolizumab Trial NCT06444815 (KaliVir): Phase 1 Study for Mesothelioma
KaliVir Immunotherapeutics PHASE1 clinical trial testing pembrolizumab (Keytruda) for mesothelioma patients. Trial NCT06444815 is now recruiting.
9/11 Mesothelioma Crisis Still Unfolding
The mesothelioma toll among 9/11 first responders and survivors is just beginning. Experts warn the worst is yet to come.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT06362369)
7 Hills Pharma, LLC PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma patients. Trial NCT06362369 is now recruiting.
DENIM Trial: Vaccine Did Not Extend Survival
The Phase 2/3 DENIM trial found that dendritic cell vaccination did not extend overall survival for mesothelioma patients after chemotherapy.
Immunotherapy Trial: Phase 1 Study for Mesothelioma
Baylor College of Medicine PHASE1/PHASE2 clinical trial testing immunotherapy for mesothelioma patients. Trial NCT05932199 is now recruiting.
Immunotherapy Trial NCT06477419 (MSK): Phase 2 Study for Mesothelioma
Memorial Sloan Kettering Cancer Center PHASE2 clinical trial testing immunotherapy for mesothelioma patients. Trial NCT06477419 is now recruiting.
CAR-T Trial: Phase 1 Study for Pleural Mesothelioma
Suzhou Maximum Bio-tech Co., Ltd. PHASE1 clinical trial testing CAR-T cell therapy for mesothelioma patients. Trial NCT06726564 is now recruiting.
MARS 2: Chemo Outperformed Surgery
The landmark MARS 2 trial found that chemotherapy alone led to better survival than surgery plus chemotherapy for pleural mesothelioma patients.
CAR-T Trial NCT06051695 (A2 Biotherapeutics): Phase 1/2 Study for Mesothelioma
A2 Biotherapeutics Inc. PHASE1/PHASE2 clinical trial testing CAR-T cell therapy for mesothelioma patients. Trial NCT06051695 is now recruiting.
Pembrolizumab Phase 2 Trial for Pleural Mesothelioma
Hyogo Medical University PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma patients. Trial NCT06318286 is now recruiting.
CAR-T Trial NCT06256055 (UTC Therapeutics): Phase 1 Study for Mesothelioma
UTC Therapeutics Inc. PHASE1 clinical trial testing CAR-T cell therapy for mesothelioma patients. Trial NCT06256055 is now recruiting.
ATOMIC-Meso: Quadrupled 3-Year Survival
The ATOMIC-Meso trial showed pegargiminase plus chemotherapy quadrupled 3-year survival rates in nonepithelioid mesothelioma, the most aggressive subtype.
CONFIRM Trial: Nivolumab Extends Survival
The CONFIRM trial showed nivolumab extends survival 40% in relapsed mesothelioma. Biomarker analysis reveals who benefits most.
2023 Mesothelioma Verdicts: $40M+ Awards
Major mesothelioma verdicts in 2023 included $40.5M in Illinois and $38M in New York as juries continue holding asbestos defendants accountable.
Nivolumab + Ipilimumab Phase 3 Trial (NCT06097728)
AstraZeneca PHASE3 clinical trial testing nivolumab plus ipilimumab for mesothelioma patients. Trial NCT06097728 is now recruiting.
Nivolumab + Ipilimumab Trial: Study for Mesothelioma
Istituto Oncologico Veneto IRCCS N/A clinical trial testing nivolumab plus ipilimumab for mesothelioma patients. Trial NCT06581549 is now recruiting.
HIPEC Trial NCT06057935 (Memorial Sloan Kettering): Phase 2 Study for Peritoneal Mesothelioma
PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT06057935 is recruiting.
Court Rejects J&J's 2nd Talc Bankruptcy
A federal judge rejected Johnson & Johnson's $8.9 billion settlement plan in July 2023, ruling the LTL Management bankruptcy was filed in bad faith.
Atezolizumab Trial: Phase 1 Study for Mesothelioma
Cancer Research UK PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for mesothelioma patients. Trial NCT05944237 is now recruiting.
SynKIR-110 CAR-T Gets FDA Fast-Track
FDA grants fast-track to SynKIR-110 CAR-T therapy for mesothelioma. Phase 1 trial recruiting at MD Anderson, Penn, and more.
Pembrolizumab Trial NCT05732831 (Tango Therapeutics): Phase 1/2 Study for Mesothelioma
Tango Therapeutics, Inc. PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma patients. Trial NCT05732831 is now recruiting.
Immunotherapy Trial NCT05730816 (Brigham & Women's): Phase 2 Study for Mesothelioma
Brigham and Women's Hospital PHASE2 clinical trial testing immunotherapy for mesothelioma patients. Trial NCT05730816 is now recruiting.
Atezolizumab Phase 1 Trial for Pleural Mesothelioma
University Hospital, Antwerp PHASE1/PHASE2 clinical trial testing atezolizumab (Tecentriq) for mesothelioma patients. Trial NCT05765084 is now recruiting.
Pembrolizumab Trial NCT05579366 (Genmab): Phase 1/2 Study for Mesothelioma
Genmab PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma patients. Trial NCT05579366 is now recruiting.
Nivolumab + Ipilimumab Phase 2 Trial (NCT04400539)
University Hospital, Lille PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma patients. Trial NCT04400539 is now recruiting.
EPA Proposes Chrysotile Asbestos Ban
In April 2022, the EPA proposed banning chrysotile asbestos, the only form still imported into the U.S., primarily used by the chlor-alkali industry.
HIPEC Trial NCT05001880 (NCI): Phase 2 Study for Peritoneal Mesothelioma
PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT05001880 is recruiting.
Atezolizumab Phase 3 Trial for Pleural Mesothelioma
PHASE3 clinical trial testing atezolizumab (Tecentriq) for mesothelioma. Trial NCT04996017 is recruiting.
CAR-T Trial NCT04981119 (A2 Biotherapeutics): Screening Study for Mesothelioma
A2 Biotherapeutics Inc. N/A clinical trial testing CAR-T cell therapy for mesothelioma patients. Trial NCT04981119 is now recruiting.
HIPEC Trial NCT04847063 (NCI): Phase 1 Study for Peritoneal Mesothelioma
PHASE1 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma. Trial NCT04847063 is recruiting.
J&J Creates LTL to Shield Talc Liability
Johnson & Johnson used a Texas Two-Step maneuver to transfer talc liabilities to LTL Management, which filed for bankruptcy in October 2021.
Pembrolizumab Trial NCT05086692 (Medicenna): Phase 1/2 Study for Mesothelioma
Medicenna Therapeutics, Inc. PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma patients. Trial NCT05086692 is now recruiting.
Pembrolizumab Trial NCT04897022 (Memorial Sloan Kettering): Phase 1 Study for Mesothelioma
Memorial Sloan Kettering Cancer Center PHASE1 clinical trial testing pembrolizumab (Keytruda) for mesothelioma patients. Trial NCT04897022 is now recruiting.
Nivolumab + Ipilimumab Phase 1/2 Trial (NCT04665206)
Vivace Therapeutics, Inc PHASE1/PHASE2 clinical trial testing nivolumab plus ipilimumab for mesothelioma patients. Trial NCT04665206 is now recruiting.
FDA OKs Opdivo+Yervoy for Mesothelioma
In October 2020, the FDA approved nivolumab plus ipilimumab as the first immunotherapy for mesothelioma, marking the first new treatment in 16 years.
CheckMate-743: Immunotherapy Beats Chemo
CheckMate-743 trial shows nivolumab plus ipilimumab extends median survival to 18.1 months vs 14.1 months with chemotherapy. 3-year survival doubles.
Immunotherapy Trial NCT03935893 (Udai Kammula): Phase 2 Study for Mesothelioma
Udai Kammula PHASE2 clinical trial testing immunotherapy for mesothelioma patients. Trial NCT03935893 is now recruiting.
FDA Approves Optune Lua for Mesothelioma
In May 2019, the FDA approved the NovoTTF-100L System (Optune Lua) for mesothelioma, the first new treatment option since pemetrexed in 2004.
Pembrolizumab Trial NCT03556228 (VM Oncology): Phase 1/2 Study for Mesothelioma
VM Oncology, LLC PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma patients. Trial NCT03556228 is now recruiting.
Zadroga Act: Permanent Care for 9/11 Responders
The 2015 Zadroga Act reauthorization made the World Trade Center Health Program permanent, ensuring continued care for 9/11 responders.